Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jul
02
Today In Oncology
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma
Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells
Can Hormone Therapy Affect Breast Cancer Risk in Younger Women
Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo